Literature DB >> 19705489

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.

Pratap Singh1, Aaron M LeBeau, Hans Lilja, Samuel R Denmeade, John T Isaacs.   

Abstract

Prostate Specific Antigen's (PSA) role as a biomarker for prostate cancer is well established but the physiological role of its serine protease activity in the pathobiology of normal prostate and prostate carcinogenesis remains largely unknown. In light of recent studies that implicate PSA's enzymatic activity in the initiation and/or progression of prostate cancer, we performed a molecular modeling study of substrate binding at the catalytic site of PSA wherein a PSA-selective substrate (HSSKLQ) was docked in an acyl-enzyme conformation to a three-dimensional homology model of PSA. Additionally, virtual positional scanning studies were conducted to gain mechanistic insights into substrate recognition of PSA. Subsequently, 13 novel peptide substrates of 6-aa length and four peptide substrates with varying length were synthesized and assayed for PSA hydrolysis to evaluate the experimental validity of docking insights. Additionally, six novel aldehyde-containing transition state analog inhibitors were synthesized and tested for their inhibitory potencies. The experimental data on the hydrolysis rates of the newly synthesized substrates and inhibitory potencies of the aldehyde peptides agreed with the docking predictions, providing validation of the docking methodology and demonstrating its utility towards the design of substrate-mimetic inhibitors that can be used to explore PSA's role in the pathobiology of prostate cancer. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705489      PMCID: PMC4559854          DOI: 10.1002/prot.22524

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  30 in total

1.  Spot synthesis: observations and optimizations.

Authors:  A Kramer; U Reineke; L Dong; B Hoffmann; U Hoffmüller; D Winkler; R Volkmer-Engert; J Schneider-Mergener
Journal:  J Pept Res       Date:  1999-10

2.  Correlation of low-barrier hydrogen bonding and oxyanion binding in transition state analogue complexes of chymotrypsin.

Authors:  D Neidhart; Y Wei; C Cassidy; J Lin; W W Cleland; P A Frey
Journal:  Biochemistry       Date:  2001-02-27       Impact factor: 3.162

3.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

4.  Backbone amide linker (BAL) strategy for Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) solid-phase synthesis of peptide aldehydes.

Authors:  Joseph C Kappel; George Barany
Journal:  J Pept Sci       Date:  2005-09       Impact factor: 1.905

5.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 6.  Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?

Authors:  Simon A Williams; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Prostate       Date:  2007-02-15       Impact factor: 4.104

7.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

8.  Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts.

Authors:  X Huang; C T Knoell; G Frey; M Hazegh-Azam; A H Tashjian; L Hedstrom; R H Abeles; S N Timasheff
Journal:  Biochemistry       Date:  2001-10-02       Impact factor: 3.162

9.  Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors.

Authors:  C S Killian; D A Corral; E Kawinski; R I Constantine
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

10.  Crystal structures of five bovine chymotrypsin complexes with P1 BPTI variants.

Authors:  Honorata Czapinska; Ronny Helland; Arne O Smalås; Jacek Otlewski
Journal:  J Mol Biol       Date:  2004-12-03       Impact factor: 5.469

View more
  8 in total

Review 1.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 2.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

3.  Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.

Authors:  Raghunath Shobana; Siba K Samal; Subbiah Elankumaran
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

4.  Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors.

Authors:  Maya B Kostova; D Marc Rosen; Ying Chen; Ronnie C Mease; Samuel R Denmeade
Journal:  J Med Chem       Date:  2013-06-04       Impact factor: 7.446

5.  A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.

Authors:  Scott Lovell; Leran Zhang; Thomas Kryza; Anna Neodo; Nathalie Bock; Elena De Vita; Elizabeth D Williams; Elisabeth Engelsberger; Congyi Xu; Alexander T Bakker; Maria Maneiro; Reiko J Tanaka; Charlotte L Bevan; Judith A Clements; Edward W Tate
Journal:  J Am Chem Soc       Date:  2021-06-04       Impact factor: 16.383

6.  Characterization of the prostate-specific antigen (PSA) catalytic mechanism: a pre-steady-state and steady-state study.

Authors:  Luigi Tomao; Diego Sbardella; Magda Gioia; Alessandra Di Masi; Stefano Marini; Paolo Ascenzi; Massimo Coletta
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

7.  Mechanism of semen liquefaction and its potential for a novel non-hormonal contraception†.

Authors:  Prashanth Anamthathmakula; Wipawee Winuthayanon
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

Review 8.  Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.

Authors:  John T Isaacs; William Nathaniel Brennen; Søren Brøgger Christensen; Samuel R Denmeade
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.